Cutaneous T cell lymphoma: Translating immunobiology into therapeutic opportunities

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 1, 2008, Pages 43-54

  Berger, C L ^a   Heald, P ^a   Girardi, M ^a   Edelson, R L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Cutaneous T cell lymphoma; Dendritic cells; Lymphoma, T cell, Cutaneous; T lymphocytes, regulatory

Indexed keywords

2 DEOXYCOFURMYCIN; ALEMTUZUMAB; BEXAROTENE; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYTOKINE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; ETRETIN; ETRETINATE; HYBRID PROTEIN; ISOTRETINOIN; METHOTREXATE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RETINOIC ACID; RETINOID; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CELL FUNCTION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNIZATION; IMMUNOBIOLOGY; NEUROTOXICITY; PHENOTYPE; PHOTOTHERAPY; PUVA; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TRANSLATION INITIATION;

EID: 42249113996     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Edelson R. Cutaneous T cell lymphoma (mycosis fungoides, Sezary syndrome and other variants). J Am Acad Dermatol 1980;2:89-106.
2. Girardi M, Heald P, Wilson L. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-88.
3. Willemze R, Jaffe E, Burg G, Cerroni L, Berti E, Swerdlow S et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-83.
4. Kung P, Berger C, Estabrook A, Edelson R. Monoclonal antibodies for clinical investigation of human T lymphocytes. Int J Dermatol 1983;22:67-74.
5. Picker L, Michie S, Rott L, Butcher E. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-68.
6. Fuhlbrigge R, Kieffer J, Armerding D, Kupper T. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;6654:978-81.
7. Volkenandt M, Wienecke R, Tiemann M. Detection of monoclonal lymphoid cell populations by polymerase chain reaction technology. Dermatol Clin 1994;12:341-9.
8. Dalloul A, Laroche L, Bagot M, Mossalayi M, Fourcade C, Thacker D et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest 1992;90:1054-60.
9. Marolleau J, Baccard M, Flageul B, Rybojad M, Laroche L, Verola O et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574-9.
10. Baron E, Stevens S. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther 2003;16:303-10.
11. Alcay J, Craig J, Kripke M. Alterations in Langerhans cells and Thy-1+ dendritic epidermal cells in murine epidermis during evolution of ultraviolet radiation-induced skin cancers. Cancer Res 1989;49:4591-6.
12. Parrish J, Fitzpatrick T, Tanenbaum I, Pathak M. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974;291:1207-11.
13. Kim Y. Management with topical nitrogen mustard in mycosis fungoides. Dermatologic Ther 2003;16:288-9.
14. Zackheim H. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther 2003;16:283-7.
15. Jones G, Hoppe R, Glatstein E. Electron treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1955;9:1057-76.
16. Dillman R, Beauregard J, Shawler D, Halpern S, Markman M, Ryan K et al. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Response Mod 1986;5:394-410.
17. Kleindienst P, Wiethe C, Lutz MB, Brocker T. Simultaneous induction of CD4 T cell tolerance and CD8 T cell immunity by semimature dendritic cells. J Immunol 2005;174:3941-7.
18. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235-47.
19. Khattri R, Cox T, Yasayko S, Ramsdell F. An essential role for scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-42.
20. Coffer P, Burgering B. Forkhead-box transcription factors and their role in the immune system. Nat Rev 2004;4:889-99.
21. Edelson R, Kirkpatrick G, Shevach E, Schein P, Green I, Lutzner MA. Preferential cutaneous infiltraton by thymus-derived lymphocytes. Ann Intern Med 1974;80:685-92.
22. Broder S, Edelson R, Lutzner M, Nelson DI, McDermott RP, Durn ME et al. The Sezary syndrome: a malignant proliferation of helper T cells. J Clin Invest 1976;58:1297-306.
23. Berger CL, Warburton D, Raafat J, LoGerfo P, Edelson RL. Cutaneous T-cell lymphoma: neoplasm of T cells with helper activity. Blood 1979;4:642-51.
24. Edelson RL, Berger C, Raafat J, Warburton D. Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. J Invest Dermatol 1979;73:548-50.
25. Berger CL, Eisenberg A, Soper L, Chow J, Simone J, Gapas Y et al. Clonal rearrangements of the T β gene and dual genotypes in cutaneous T cell lymphoma. J Invest Dermatol 1988;90:73-7.
26. Charley M, McCoy J, Deng J, Jegasothy B. Anti-V region antibodies as "almost clonotypic" reagents for the study of cutaneous T cell lymphomas and leukemias. J Invest Dermatol 1990;95:614-7.
27. Foss F, Raubitscheck A, Mulshine J, Fleisher T, Reynolds J, Paik C et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998;4:2691-700.
28. Foss F, Waldmann T. Interleukin-2 receptor-directed therapies for cutaneous lymphomas. Hematol Oncol Clin North Am 2003;17:1449-58.
29. Abrams J, Lessin SR, Ghosh S, Nowell PC, Ju W, Vonderheid EC et al. Malignant and nonmalignant T cell lines from human T cell lymphotropic virus type I-negative patients with Sezary syndrome. J Immunol 1991;146:1455-62.
30. Dôbbeling U, Dummer R, Laine E, Potoczna N, Qin J-Z, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998;92:252-8.
31. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002;99:2929-38.
32. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage-colony stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor-α. J Exp Med 1994;179:1109-18.
33. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y-H et al. Immunobiology of dendritic cells. Ann Rev Immunol 2000,18:767-811.
34. Miceli M, Parnes J. Role of CD4 and CD8 in T cell activation and differentiation. Adv Immunol 1998;53:59-122.
35. Steinman R, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-6.
36. von Herrah M, Harrison L. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003;3:223-32.
37. Sakaguchi S, Wood K. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
38. Wang H, Wang R-F. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect 2005;7:1056-62.
39. Antony P, Restifo N. CD4+CD25+ T regulatory cells, immunotherapy of cancer and interleukin-2. J Immunother 2005;28:120-8.
40. Vignier M, Lemaitre F, Verola O, Cho M, Gorochov G, Dubertret L et al. Foxp3 expressing CD4+ CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
41. Woo EY, Chu CS, Goletz T, Schlienger K, Yeh H, Coukos G et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2002;61:4766-72.
42. Liyanage U, Moore T, Joo H, Tanaka Y, Herrmann V, Doherty G et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
43. Berger C, Xu A, Hanlon D, Lee C, Schechner J, Glusac E et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001;4:438-47.
44. Edelson RL, Berger CL, Gasparro FP, Jegasothy B, Heald P, Wintroub B et al. Treatment of leukemic cutaneous T-cell lymphoma with extracorporeally-photoactivated 8-methoxypsoralen. N Engl J Med 1987;316:297-303.
45. Edelson R, Facktor M, Andrews A, Lutzner M, Schein P. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. N Engl J Med 1974;291:293-4.
46. Gilchrest B, Parrish J, Tanenbaum L, Haynes H, Fitzpatrick T. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976;38:683-9.
47. Berger C, Cantor C, Welsh J, Dervan P, Gasparro F, Edelson R. Inhibition of lymphocyte proliferation by water soluble psoralen derivatives. Ann NY Acad Sci 1985;446:80-90.
48. Berger C, Hanlon D, Kanada D, Girardi M, Edelson R. Transimmunization, a novel approach for tumor immunotherapy. Trans Apher Sci 2002;3:205-16.
49. Girardi M, Berger C, Wilson L, Christensen I, Thompson K, Glusac E et al. Transimmunization for cutaneous T cell lymphoma: a Phase 1 study. Leuk Lymph 2006;47:1495-503.
50. Gudas L. Retinoids, retinoid response genes, cell differentiation and cancer. Cell Growth Diff 1992;3:655-62.
51. Zhang C, M D. Retinioids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 2003;16:322-30.
52. Blumberg B, Evans R. Orphan nuclear receptors-new ligands and possibilities. Gene Dev 1998;12:3144-55.
53. Rook A, Kubin M, Fox F, Niu Z, Cassin M, Vowels B et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann N Y Acad Sci 1996;795:310-8.
54. Meunier L, Bohjanen K, Voorhees J, Cooper K. Retinoid acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11C, a beta-2 integrin critically involved in T-cell activation. J Invest Dermatol 1994;103:775-9.
55. Budgin J, Richardson S, Newton S, Wysocka M, Zaki M, Benoit B et al. Biological effects of Bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005;14:315-21.
56. Gorgun G, Foss F. Immunomodulatory effects of RXR retinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin difitox. Blood 2002;100:1399-403.
57. McGinnis KS, Junkins-Hopkins J, Crawford G, Shapiro M, Rook A, Vittorio C. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004;50:375-9.
58. Thirdborough S, Radcliffe J, Friedmann P, Stevenson F. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer Res 2002;62:1757-60.
59. Morris J, Waldmann T. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000;1(Suppl I):109-14.
60. Dearden C, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002;19 Suppl:S27-S32.
61. Nichols J, Foss F, Kuzel T, LeMaistre C, Platanias L, Ratain M et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997;33 Suppl:S34-S6.
62. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19: 376-88.
63. Olsen E. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003;16:311-21.
64. Herberman R, Ortaldo J, Mantovani A, Hobbs B, Kung H, Pestka S. Effect of recombinant interferon on cytotoxic activity of NK cells and monocytes. Cell Immunol 1982;67:160-7.
65. Fellows M, Kamoun M, Gresser I, Bono R. Enhanced expression of HLA antigens and β2-microglobulin on interferon-treated human lymphoid cells. Eur J Immunol 1979;9:446-9.
66. Rook A, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:997-1010.
67. Jonasch E, Haluska F. Interferon in oncologic practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.
68. Tracey L, Spiteri I, Ortiz P, Lawler M, Piris M, Villuendas R. Transcriptional response of T cells to IFN-α: changes induced in IFN-α-sensitive and resistant cutaneous T cell lymphoma. J Interferon Cyto Res 2004;24:185-95.
69. Rook A, McGinnis K, Richardson S, Budgin J, Wysocka M, Benoit B et al. The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma. Dermatologic Ther 2003;16:331-6.
70. Wysocka M, Zaki M, French L, Chehimi J, Shapiro M, Everetts S et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002;100: 3287-94.
71. Rook A, Wood G, Yoo E, Elenitsas R, Kao D, Sherman M et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-8.
72. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N et al. Cutaneous T cell lymphoma, malignant proliferation of T-regulatory cells. Blood 2005;105:1640-7.
73. Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997;186:1763-8.
74. Wilson L, Jones G, Kim D, Rosenthal D, Christensen I, Edelson R et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000;43:54-60.
75. Jones G, Wong R, Kastikainen J, Farrar N, Fox-Goguen L, Sur R. 15-year results of total skin electron beam (TSEB) radiation as first-line monotherapy for newly diagnosed stage IA-IB mycosis fungoides (MF). Int J Radiat Oncol Biol Phys 2003;57 Suppl:S291.
76. Kuzel T. Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome. Dermatol Ther 2003;16:366-1.
77. McDonald C, Bertino J. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorium factor. Cancer Treat Rep 1978;62:1009-914.
78. Saven A, Piro L. The newer purine analogs. Cancer 1993;72:3470-83.
79. Kurzrock H, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1990;17:3117-21.
80. Zinzani P, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;16: 2603-6.
81. Argiris A, Heald P, Kuzel T, Foss F, DiStasio S, Cooper D et al. Phase II trial of 9-aminocampothecin as a 72-hour infusion in cutaneous T-cell lymphoma. Invest New Drugs 2001;19:321-6.
82. Wollina U, Graefe T, Karie K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000;42:40-6.
83. 6-alkylguanine DNA alkyltrasferase. Prog Nucl Acid Res Mol Biol 1995;51:167-223.
84. Piekarz R, Robey R, Sandor V, Bakke S, Wilson W, Dahmoush L et al. Inhibitor of histone deacetylation depsipeptide (FR901228) in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865-8.
85. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid E, Nichols C et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003;197:1477-88.